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background: We previously reported a 12-wk trial of alirocumab or placebo in 77 patients with heterozygous familial hypercholesterolemia (HeFH) 
on statin±ezetimibe, showing dose-related mean LDL-C reductions up to 68%. We now report safety and efficacy after 52 wks of a 4-yr open-label 
treatment (OLT) extension (NCT01576484).
methods: Following study drug washout, 58 patients (75%) from the parent trial entered OLT with alirocumab 150 mg every 2 wks (Q2W) and 
existing baseline lipid therapy. If calculated LDL-C was <25 mg/dL on 2 consecutive visits, investigators could reduce the alirocumab dose.
results: After mean (SD) duration of 65 (18) wks, 54 patients continued in OLT (2 withdrew consent; 1 adverse event (AE) unrelated to treatment; 
1 lost to follow-up). Mean LDL-C decreased from 153 (baseline) to 56-67 mg/dL (wks 12-64; 57- 66% reduction, all p<0.0001) [Table]. Patients 
with LDL-C <25 mg/dL at 1 and 2 consecutive visits were 40% and 22%, respectively. Median Lp(a) reductions ranged from 18-25% (all p<0.0001); 
changes in all lipids were consistent with the parent trial. Compliance to alirocumab Q2W dosing was >90%. Most frequent AE was injection site 
bruising. No significant liver or muscle enzyme elevations occurred. Frequency and titers for antidrug antibodies were low.
conclusion: Alirocumab 150 mg Q2W for 1 yr in HeFH patients was well tolerated with >90% compliance. AEs were consistent with phase 2 trials. 
When added to statin±ezetimibe, LDL-C reductions of ~60% and ~20% in Lp(a) were maintained.
 
